FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
For Immediate Release: September 24, 2021 (repost from FDA) The U.S. Food and Drug Administration today took steps aimed at…
09/24/2021
FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
For Immediate Release: September 24, 2021 (repost from FDA) The U.S. Food and Drug Administration today took steps aimed at…
|
09/24/2021
International Survivor Spotlight: José Correia, Portugal
By Mara Klecker José Correia’s melanoma diagnosis was nearly a quarter-century ago, but he is committed to spreading awareness about…
|
|
09/24/2021
Making the Cut For Melanoma: A Mom’s Motivation
By Mara Klecker As a social service director working in long-term care, Traci Cunningham made a promise to her…
|
|
09/24/2021
President’s Letter | September 2021
From the Desk of Samantha Guild As I reviewed the articles for this month’s newsletter, I thought about the fact…
|
09/24/2021
What is Translational Medicine?
By Maria Libera Ascierto, MS, PhD Associate Professor Translational Cancer Immunology Director “The Rosalie and Harold R Brown Cancer Immunotherapy”…
|
09/24/2021
Melanoma by the State: Oregon
Let’s start with some fun facts about Oregon: Oregon boasts the deepest lake in the U.S., Crater Lake, with a…
|
09/24/2021
Motherhood and Melanoma: Raleigh Minning, Stage III Melanoma Survivor
By Mara Klecker One of the only times Raleigh Minning cried during her melanoma journey was when she thought of…
|
09/20/2021
Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
|
|
09/20/2021
USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
|
|
09/18/2021
Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma
LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
|
|
Recent Posts
Dec. 12, 2024
Navigating Melanoma Together: 2024 Podcast Wrap-Up
Dec. 10, 2024
Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel
Dec. 09, 2024
Managing Melanoma During the Holiday Season
Dec. 05, 2024
Beyond the Clinic’s New Host: Dr. Sam Siegel Brings a Fresh Voice to Survivorship
Dec. 03, 2024